title: Differential healing responses in polymer- and nonpolymer-based sirolimus-eluting stents.
abstract: OBJECTIVE
  We compared the healing and inflammatory responses of polymer-free bare-metal stents (BMS), polymer-free sirolimus-eluting stents (SES) and polymer-free sirolimus-eluting stents plus estradiol (SES+ED) to Cypher drug-eluting stents (CDES) in a rabbit model of overlapping stent placement.
  
  
  BACKGROUND
  Inflammatory responses to polymers and delayed healing remain important safety issues associated with CDES. Whether nonpolymeric stents that elute sirolimus or sirolimus and estradiol provoke less inflammation and heal better is unknown.
  
  
  METHODS
  Twenty-eight rabbits received 2 overlapping stents in each iliac artery: SES, SES+ED, BMS, or CDES, and vessels were harvested at 28 days for histology and scanning electron microscopy.
  
  
  RESULTS
  Although similar at nonoverlapping segments, neointimal thickness within the overlap site of CDES was significantly less than in SES, SES+ED, and BMS (0.07 +/- 0.04 mm vs. 0.16 +/- 0.03 mm, 0.14 +/- 0.03 mm, and 0.15 +/- 0.03 mm, p < 0.0001). Endothelialization was greater in SES, SES+ED, and BMS compared with CDES in nonoverlapping sections (80.0 +/- 5.0% vs. 95.3 +/- 5.0%, 97.5 +/- 2.5%, and 96.7 +/- 3.8%; p = 0.0028) and overlapping sections (85.8 +/- 2.9% vs. 90.8 +/- 6.3%, 89.2 +/- 6.3%, and 48.3 +/- 2.9%; p < 0.0001). The number of luminal eosinophils was also less in overlapping sections of SES, SES+ED, and BMS versus CDES but was similar in nonoverlapping sections.
  
  
  CONCLUSIONS
  Polymer-free stents coated with SES or SES+ED result in less robust neointimal suppression but markedly improved arterial healing compared with CDES in the rabbit model.
authors.affiliation: Department of Internal Medicine, Massachusetts General Hospital, Boston, USA.
authors.forename: Michael C
authors.initials: MC
authors.lastname: John
authors.forename: Rainer
authors.initials: R
authors.lastname: Wessely
authors.forename: Adnan
authors.initials: A
authors.lastname: Kastrati
authors.forename: Albert
authors.initials: A
authors.lastname: Schömig
authors.forename: Michael
authors.initials: M
authors.lastname: Joner
authors.forename: Mayu
authors.initials: M
authors.lastname: Uchihashi
authors.forename: Johanna
authors.initials: J
authors.lastname: Crimins
authors.forename: Scott
authors.initials: S
authors.lastname: Lajoie
authors.forename: Frank D
authors.initials: FD
authors.lastname: Kolodgie
authors.forename: Herman K
authors.initials: HK
authors.lastname: Gold
authors.forename: Renu
authors.initials: R
authors.lastname: Virmani
authors.forename: Aloke V
authors.initials: AV
authors.lastname: Finn
mesh_terms: D000800:Angioplasty, Balloon / Q000009:adverse effects / Q000295:instrumentation*; D000818:Animals; D002317:Cardiovascular Agents / Q000008:administration & dosage*; D016207:Cytokines / Q000378:metabolism; D054855:Drug-Eluting Stents; D005343:Fibrinolytic Agents / Q000627:therapeutic use; D007083:Iliac Artery / Q000187:drug effects* / Q000293:injuries / Q000378:metabolism / Q000648:ultrastructure; D007249:Inflammation / Q000209:etiology / Q000378:metabolism / Q000473:pathology / Q000517:prevention & control*; D036341:Intercellular Signaling Peptides and Proteins / Q000378:metabolism; D008670:Metals; D008855:Microscopy, Electron, Scanning; D023421:Models, Animal; D009924:Organ Culture Techniques; D011108:Polymers; D011474:Prosthesis Design; D011817:Rabbits; D020123:Sirolimus / Q000008:administration & dosage*; D015607:Stents; D014945:Wound Healing / Q000187:drug effects*
chemical_list: D002317:Cardiovascular Agents; D016207:Cytokines; D005343:Fibrinolytic Agents; D036341:Intercellular Signaling Peptides and Proteins; D008670:Metals; D011108:Polymers; D020123:Sirolimus